Vilka är öppettiderna?

Måndag 08:00 - 17:00 Tisdag 08:00 - 17:00 Onsdag 08:00 - 17:00 Torsdag 08:00 - 17:00 Fredag 08:00 - 17:00

Alzecure

Hem
Sverige
Huddinge
Alzecure

Alzecure is a non-profit research foundation with funding initially from donations and grants from individuals, non-profit organizations and governments.

AlzeCure develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The objective of Alzecure Foundation is to enhance scientific research in age related diseases, primarily Alzheimer’s disease and other neurodegenerativ

e conditions, with the aim to develop new therapies, diagnostics, treatments and medical technologies. We develop innovative therapies for the treatment of Alzheimer ́s disease and related neurodegenerative disorders, as well as unique medical technologies that will enable us to detect and monitor treatment effect in patients. This organization form provides stability for continuous evaluation of novel concepts from academic research, but is combined with the overall aim of AlzeCure to commercialize its successful projects. Promising projects will be spun-out as commercial companies, subsidiaries to Alzecure, allowing external partners and investors to buy-in, contribute and collaborate

07/05/2026

AlzeCure Pharma published Q1 2026 report.

Continued positive development

“During the first quarter of 2026, our focus was on preparing the Phase II study in Alzheimer’s patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). In addition, we successfully advanced the Phase Ib clinical trial with ACD856, further expanding the therapeutic dose window to increase our opportunities to address multiple indications. During the quarter, we also continued preparing for a potential registrational study for the pain project Painless ACD440. In February, ACD440 was granted orphan drug designation by the European Medicines Agency. We also remained active in business development at international conferences and published new data from our NeuroRestore project at the world-leading Alzheimer’s conference AD/PD 2026, which was held in Copenhagen in March.” – Martin Jönsson, CEO

Significant events during the period January – March 2026

In February 2026, the pain project ACD440 was granted orphan drug designation in Europe by the EMA.

AlzeCure presented new preclinical data concerning NeuroRestore ACD856 at the AD/PD Alzheimer’s conference in mid-March.

Significant events after the end of the period

In April, the company announces that the last participant has completed treatment in AlzeCure's clinical phase Ib study with NeuroRestore ACD856.
In April, the board of directors, supported by the authorization granted by the Annual General Meeting on May 14, 2025, decides to carry out a rights issue of approximately SEK 30.1 million. The issue is, free of charge, 100 percent secured.

Read the full report here:https://www.alzecurepharma.se/en/wp-content/uploads/sites/2/2026/04/alzecure-q1-2026-eng-final-260505.pdf

AlzeCure Pharma Life Science Cluster Flemingsberg

07/05/2026

New AlzeCure publication on our pain project TrkA-NAM targeting osteoarthritis

Our article on the analgesic and knee joint protective effects of TrkA-NAM ACD137 in a model of osteoarthritis is now available online. In moments like this, I miss paper reprints, so I settled for this AI-generated 'happy scientist figure' with a virtual preprint.

TrkA-NAM ACD137 is a highly potent and selective negative allosteric modulator of TrkA for the treatment of pain.

The on-line version can be found using the link below: https://www.degruyterbrill.com/document/doi/10.1515/sjpain-2026-0007/html

Pontus Forsell Märta Segerdahl Johan Sandin Maria Backlund Cristina Parrado Veronica Lidell Gunnar Nordvall AlzeCure Pharma Life Science Cluster Flemingsberg

28/04/2026

Intervju om AlzeCures förestående företrädesemission under maj 2026

Intervju hos Redeye av analytikern Filip Lindkvist med AlzeCures vd Martin Jönsson om den förestående företrädesemissionen som AlzeCure kommer genomföra under maj 2026 vilken redan är säkrad till 100%, utan ersättning till externa parter. Bolaget planerar att ta in drygt 30,1 MSEK

Se intervjun här: https://www.youtube.com/watch?v=CyDLQ4EdVGU

Till pressreleasen om emissionen: https://www.alzecurepharma.se/sv/disclaimer/?redirect=https://www.alzecurepharma.se/sv/alzecure-pharma-genomfor-en-till-100-procent-sakerstalld-foretradesemission-om-ca-301-msek/

24/04/2026

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure today announced that the Board of Directors has resolved on a new share issue of approximately SEK 30.1 million, in a coming rights issue, which is secured to 100%, without cost for the Company.

AlzeCure is currently engaged in active and concrete discussions with several external parties regarding potential licensing and collaboration agreements for the Company's drug candidates. The Rights Issue is carried out to strengthen the cash position and provide resources for business development, pending these discussions.

The Rights Issue is fully secured to 100 percent as the Company's two major shareholders, BWG Invest Sàrl and Sjuenda Holding AB, have undertaken, free of charge, to subscribe for all shares not subscribed for by other shareholders or subscription rights holders. Subscription undertakings from the Company's two major shareholders, Board of Directors, management and other larger shareholders amount to approximately SEK 9.3 million, corresponding to approximately 31 percent of the Rights Issue.

"We are very pleased that our major shareholders, as well as all members of the Board of Directors, support our projects by committing to subscribe for their respective pro-rata shares in the Rights Issue. The Company is now at a stage where business development is critical to realizing the value inherent in the project portfolio. The Company is engaged in active discussions with several parties regarding potential licensing and collaboration agreements, and through this share issue the cash position is strengthened to intensify out-licensing efforts and capitalize on the opportunities being discussed. The strong support from existing shareholders means that the transaction is, free of charge, 100% secured, which is very positive," says Martin Jönsson, CEO of AlzeCure Pharma AB.

The subscription price is SEK 1.31 per share.

Read the full press release here: https://www.alzecurepharma.se/en/alzecure-pharma-carries-out-a-fully-secured-rights-issue-of-approximately-sek-30-1-million/

AlzeCure Pharma ABG Sundal CollierLife Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin JönssonAlzheimerfonden

24/04/2026

AlzeCure Pharma genomför en till 100 procent säkerställd företrädesemission om ca 30,1 MSEK

AlzeCure meddelade idag att styrelsen har beslutat att genomföra en företrädesemission om cirka 30,1 MSEK vilken är till 100% säkerställd till utan kostnad för bolaget, dvs ingen ersättning för att teckna i emissionen kommer att betalas.

AlzeCure för idag aktiva och konkreta samtal med flera externa aktörer kring möjliga licens- och samarbetsaffärer avseende bolagets läkemedelskandidater. Företrädesemissionen genomförs för att stärka kassan och ge resurser till affärsutveckling, i avvaktan på dessa samtal.

Företrädesemissionen är till 100 procent säkerställd genom att Bolagets två huvudägare, BWG Invest Sàrl och Sjuenda Holding AB, vederlagsfritt, förbinder sig att teckna samtliga aktier som inte tecknas av andra aktieägare eller teckningsberättigade.

Teckningsförbindelser från Bolagets två huvudägare, styrelse, ledning och andra större aktieägare uppgår till cirka 9,3 MSEK, motsvarande cirka 31 procent av Företrädesemissionen.

”Det är mycket glädjande att våra större ägare, såväl som samtliga styrelsemedlemmar stödjer våra projekt genom att förbinda sig att teckna sina respektive andelar av Företrädesemissionen. Bolaget befinner sig nu i en fas där affärsutveckling är avgörande för att realisera det värde som finns i projektportföljen. Bolaget för aktiva
diskussioner med flera aktörer om eventuella licens- och samarbetsaffärer och genom denna emission stärks kassan för att kunna intensifiera utlicensieringsarbetet och utnyttja de möjligheter som diskuteras. Det starka stödet av existerande ägare gör att transaktionen, vederlagsfritt, är 100% säkerställd, vilket känns mycket positivt,” säger Martin Jönsson, VD på AlzeCure Pharma AB.

Teckningskursen är satt till 1,31 SEK.

Läs den fullständiga pressreleasen här: https://www.alzecurepharma.se/sv/disclaimer/?redirect=https://www.alzecurepharma.se/sv/alzecure-pharma-genomfor-en-till-100-procent-sakerstalld-foretradesemission-om-ca-301-msek/

AlzeCure Pharma ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin Jönsson

22/04/2026

Attending Nordic Health Summit Japan
- April 23-24th 2026

Happy to attend the Nordic Health Summit in Japan, Tokyo to present AlzeCure and our projects in Alzheimer’s and pain for pharmacies companies, investors and other potential partners.

This year the meeting is also having Japan’s Nobel Prize laureate in medicine from 2025, Professor Shimon Sakaguchi, attending the conference and giving a lecture, which is generating additional attention and attendees, and strengthens the ties and relationships between Japan and Sweden.

The meeting is arranged by Business Sweden together with several other Nordic organisations.

More on Professor Shimon Sakaguchi: https://www.nobelprize.org/prizes/medicine/2025/sakaguchi/facts/

Martin Jönsson AlzeCure Pharma Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Business Sweden SwedenBIO

21/04/2026

Last patient completed in the additional 1b with NeuroRestore
AlzeCure Pharma announces an important milestone: the last patient has now completed the additional Phase Ib clinical study of ACD856, the lead candidate within the NeuroRestore platform.

The study has progressed according to plan and focuses on evaluating safety, tolerability, and pharmacokinetics at higher repeated doses. ACD856 has previously demonstrated a strong safety profile and the ability to reach the brain and activate pathways linked to cognition and depression.

This progress supports continued development toward Phase II, with potential applications not only in Alzheimer’s disease but also in other areas with significant unmet medical need, such as depression.

ACD856 is a first-in-class candidate with a unique mechanism that may strengthen neuronal communication, improve cognitive function, and offer neuroprotective and anti-inflammatory effects.

Read the full press release here:https://www.alzecurepharma.se/en/wp-content/uploads/sites/2/2026/04/press-release-last-patient-has-completed-alzecures-phase-ib-clinical-study-with-neurorestore-acd856-260420.pdf

Johan Sandin Martin Jönsson AlzeCure Pharma

15/04/2026

Continuing Progress in AlzeCure
- AlzeCure Pharma Annual Report 2025.

"With strong progress and many positive events in 2025, our main priority going forward is to prepare for the Phase II clinical trial in Alzheimer’s patients with NeuroRestore ACD856, for which we have received a grant from the EIC. We continue to prepare both our pain project in knee osteoarthritis, TrkA-NAM ACD137, and Alzstatin ACD680 for Phase I clinical trials. We also remain strongly focused on business development with the aim of out-licensing one or more of our projects, including the pain project, ACD440."

Martin Jönsson
CEO of AlzeCure Pharma

Read the full report here:https://www.alzecurepharma.se/en/wp-content/uploads/sites/2/2026/04/alzecure-ar-2025-eng-260408.pdf

Martin Jönsson

02/04/2026

Happy Easter 🐣 🐣 🐣
- Have a great one.

01/04/2026

AlzeCure presenterar på Redeye Alzheimer’s Event
- 9 april

AlzeCure kommer att medverka på Redeye Alzheimer’s Theme Event den 9 april där VD Martin Jönsson och CSO Johan Sandin kommer att presentera bolaget och dess projektportfölj inom Alzheimers.

Presentationen följs av en frågestund ledd av Redeyes analytiker Filip Lindkvist.

Deltagandet livesänds och kan följas på:
https://www.redeye.se/events/1146454/redeye-theme-alzheimer-3

AlzeCure kommer presentera kl. 11:15 den 9 april 2026
Plats: Redeye, Mäster Samuelsgatan 42, Stockholm; https://www.redeye.se/events/1146454/redeye-theme-alzheimer-3

Stiftelsen Flemingsberg Science Life Science Cluster Flemingsberg Martin Jönsson Johan Sandin

30/03/2026

Presentation om AlzeCure Pharma hos Aktiespararna av CEO Martin Jönsson

Presentation om AlzeCure Pharma av CEO Martin Jönsson om bolaget och dess projekt inom Alzheimer och smärta, samt om den senaste utvecklingen och bolagets planer.

Presentationen hölls hos Aktiespararna på Stora Aktiedagarna i Stockholm den 11 mars 2026.

Till presentationen: https://www.youtube.com/watch?v=AL2-H9vwA_4

Adress

Hälsovägen 7
Huddinge
14157

Öppettider

Måndag	08:00 - 17:00
Tisdag	08:00 - 17:00
Onsdag	08:00 - 17:00
Torsdag	08:00 - 17:00
Fredag	08:00 - 17:00

Telefon

+46704979724

Webbplats

http://www.alzecure.org/, https://www.alzecurepharma.se/en/subscribe-media/, https://www.alzecurepharma.se/sv/prenumerer

Aviseringar

Var den första att veta och låt oss skicka ett mail när Alzecure postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till Alzecure:

Genvägar

Vill du placera din praktik längst upp i Klinik-listan i Huddinge?

Dela

Typ

Medicinskt labb